Digitisation | September 05, 2023
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
The 100 surgeries conducted using robotic technology span various intricate procedures in the fields of Urology, Liver Transplantation, GI surgery, Cardiac surgeries and Gynaecology
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
Centre aims to train surgeons and other healthcare professionals from India and Southeast Asia in robotic-assisted surgery
Subscribe To Our Newsletter & Stay Updated
